Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis

References

• O’Donoghue DJ, Short CD, Brenchley PE, Lawler W, Ballardie FW. Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol 1989;32:251–5.
   PubMed Web of Science ®Google Scholar
• Serratrice J, Chiche L, Dussol B, Granel B, Daniel L, Jego-Desplat S, et al. Sequential development of perinuclear ANCA-associated vasculitis and anti-glomerular basement membrane glomerulonephritis. Am J Kidney Dis 2004;43:e14.1–e14.5.
   PubMed Web of Science ®Google Scholar
• Olson SW, Arbogast CB, Baker TP, Owshalimpur D, Oliver DK, Abbott KC, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 2011;22:1946–52.
   PubMed Web of Science ®Google Scholar
• Chan PSJ, Leung MH. Sequential occurrence of anti-glomerular basement membrane disease 9 years after anti-neutrophil cytoplasmic antibody-associated vasculitis. Oxf Med Case Rep 2016;2016:91–3.
   PubMedGoogle Scholar
• Ohashi N, Namikawa A, Ono M, Iwakura T, Isobe S, Tsuji T, et al. The sequential development of antiglomerular basement membrane nephritis and myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis. Intern Med 2017;56:2617–21.
   PubMed Web of Science ®Google Scholar
• Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 1997;8:376–85.
   PubMed Web of Science ®Google Scholar
• McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol 2017;12:1162–72.
   PubMed Web of Science ®Google Scholar
• Bosch X, Mirapeix E, Font J, Borrellas X, Rodríguez R, López-Soto A, et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 1991;36:107–13.
   PubMed Web of Science ®Google Scholar
• Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66:1535–40.
   PubMed Web of Science ®Google Scholar
• Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JWC. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005;46:253–62.
   PubMed Web of Science ®Google Scholar
• Zhao J, Yang R, Cui Z, Chen M, Zhao M-H, Wang H-Y. Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin Pract 2007;107:c56–62.
   PubMedGoogle Scholar
• Srivastava A, Rao GK, Segal PE, Shah M, Geetha D. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody. Clin Rheumatol 2013;32:1317–22.
   PubMed Web of Science ®Google Scholar
• McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 2017;92:693–702.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827–32.
   PubMed Web of Science ®Google Scholar
• Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 2018;94:1177–88.
   PubMed Web of Science ®Google Scholar
• Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628–36.
   PubMed Web of Science ®Google Scholar
• Savage CO, Pusey CD, Bowman C, Rees AJ, Lockwood CM. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986;292:301–4.
   PubMed Web of Science ®Google Scholar
• Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134:1033–42.
   PubMed Web of Science ®Google Scholar
• Pusey CD. Anti-glomerular basement membrane disease. Kidney Int 2003;64:1535–50.
   PubMed Web of Science ®Google Scholar
• Jayne DRW, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990;37:965–70.
   PubMed Web of Science ®Google Scholar
• Salama AD, Dougan T, Levy JB, Cook HT, Morgan SH, Naudeer S, et al. Goodpasture’s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 2002;39:1162–7.
   PubMed Web of Science ®Google Scholar
• Moulis G, Huart A, Guitard J, Fortenfant F, Chauveau D. IgA-mediated anti-glomerular basement membrane disease: an uncommon mechanism of Goodpasture’s syndrome. Clin Kidney J 2012;5:545–8.
   PubMedGoogle Scholar
• Ohlsson S, Herlitz H, Lundberg S, Selga D, Mölne J, Wieslander J, et al. Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease. Am J Kidney Dis 2014;63:289–93.
   PubMed Web of Science ®Google Scholar
• Segelmark M, Hellmark T, Wieslander J. The prognostic significance in Goodpasture’s disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 2003;94:c59–68.
   PubMedGoogle Scholar
• Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JWC, Dadoniené J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–32.
   PubMed Web of Science ®Google Scholar
• DE Zoysa J, Taylor D, Thein H, Yehia M. Incidence and features of dual anti-GBM-positive and ANCA-positive patients. Nephrology (Carlton) 2011;16:725–9.
   PubMed Web of Science ®Google Scholar